X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Unichem Lab with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB DISHMAN PHARMA UNICHEM LAB/
DISHMAN PHARMA
 
P/E (TTM) x 29.9 25.1 119.1% View Chart
P/BV x 3.1 3.3 94.0% View Chart
Dividend Yield % 0.6 0.7 90.9%  

Financials

 UNICHEM LAB   DISHMAN PHARMA
EQUITY SHARE DATA
    UNICHEM LAB
Mar-16
DISHMAN PHARMA
Mar-16
UNICHEM LAB/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs334374 89.2%   
Low Rs174129 135.0%   
Sales per share (Unadj.) Rs146.9197.8 74.3%  
Earnings per share (Unadj.) Rs11.921.2 56.1%  
Cash flow per share (Unadj.) Rs16.234.7 46.6%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.80.8 99.1%  
Book value per share (Unadj.) Rs105.1179.9 58.4%  
Shares outstanding (eoy) m90.8480.69 112.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x1.71.3 135.9%   
Avg P/E ratio x21.411.9 180.0%  
P/CF ratio (eoy) x15.77.2 216.5%  
Price / Book Value ratio x2.41.4 172.7%  
Dividend payout %16.89.4 178.3%   
Avg Mkt Cap Rs m23,07320,306 113.6%   
No. of employees `0005.70.8 684.3%   
Total wages/salary Rs m2,5585,355 47.8%   
Avg. sales/employee Rs Th2,352.519,252.7 12.2%   
Avg. wages/employee Rs Th450.96,459.5 7.0%   
Avg. net profit/employee Rs Th190.42,064.1 9.2%   
INCOME DATA
Net Sales Rs m13,34615,961 83.6%  
Other income Rs m192265 72.3%   
Total revenues Rs m13,53816,226 83.4%   
Gross profit Rs m1,6394,103 39.9%  
Depreciation Rs m3901,091 35.8%   
Interest Rs m29944 3.0%   
Profit before tax Rs m1,4122,334 60.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m-41 -336.4%   
Extraordinary Inc (Exp) Rs m-350-   
Tax Rs m293624 46.9%   
Profit after tax Rs m1,0801,711 63.1%  
Gross profit margin %12.325.7 47.8%  
Effective tax rate %20.726.7 77.6%   
Net profit margin %8.110.7 75.5%  
BALANCE SHEET DATA
Current assets Rs m5,97911,018 54.3%   
Current liabilities Rs m2,4329,517 25.6%   
Net working cap to sales %26.69.4 282.7%  
Current ratio x2.51.2 212.4%  
Inventory Days Days63110 57.1%  
Debtors Days Days6035 173.3%  
Net fixed assets Rs m6,40316,304 39.3%   
Share capital Rs m182161 112.6%   
"Free" reserves Rs m9,29312,907 72.0%   
Net worth Rs m9,54814,516 65.8%   
Long term debt Rs m2304,189 5.5%   
Total assets Rs m12,84329,805 43.1%  
Interest coverage x50.03.5 1,441.4%   
Debt to equity ratio x00.3 8.4%  
Sales to assets ratio x1.00.5 194.1%   
Return on assets %8.68.9 96.9%  
Return on equity %11.311.8 96.0%  
Return on capital %14.317.5 81.8%  
Exports to sales %29.224.8 117.9%   
Imports to sales %6.33.7 169.8%   
Exports (fob) Rs m3,9003,956 98.6%   
Imports (cif) Rs m847596 142.0%   
Fx inflow Rs m4,3564,952 88.0%   
Fx outflow Rs m1,162697 166.8%   
Net fx Rs m3,1944,255 75.1%   
CASH FLOW
From Operations Rs m1,1192,786 40.2%  
From Investments Rs m-853-1,529 55.8%  
From Financial Activity Rs m-334-941 35.5%  
Net Cashflow Rs m-68316 -21.6%  

Share Holding

Indian Promoters % 50.1 61.4 81.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 15.1 3.7 408.1%  
FIIs % 3.0 12.7 23.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 31.7 22.1 143.4%  
Shareholders   20,176 46,261 43.6%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   CADILA HEALTHCARE  TTK HEALTHCARE  ORCHID PHARMA LTD  STRIDES SHASUN LTD  J.B.CHEMICALS  

Compare UNICHEM LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Feb 23, 2018 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB - SHASUN PHARMA COMPARISON

COMPARE UNICHEM LAB WITH

MARKET STATS